J1303 HCPCS Level II code: Injection, ravulizumab-cwvz, 10 mg

J1303 is the HCPCS code for “Injection, ravulizumab-cwvz, 10 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J1303

Injection, ravulizumab-cwvz, 10 mg

Short description: Inj., ravulizumab-cwvz 10 mg

HCPCS · United States

Medicare details

The indicators CMS publishes with J1303 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Drugs
ASC
Approved for ambulatory surgical centers
Type of service
Medical care; Lump sum purchase of DME, prosthetics, orthotics
BETOS category
Other drugs
Added
Oct 1, 2019

Where J1303 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J1303Injection, ravulizumab-cwvz, 10 mg

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J1303 mean?

J1303 is the HCPCS code for “Injection, ravulizumab-cwvz, 10 mg” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J1303?

CMS lists J1303’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.